AXON - Axovant Sciences Ltd.
| Previous Close | 2.11 |
| Open | 2.12 |
| Bid | 2.12 x 1100 |
| Ask | 2.13 x 1000 |
| Day's Range | 2.07 - 2.13 |
| 52 Week Range | 1.02 - 27.98 |
| Volume | 76,840 |
| Avg. Volume | 1,592,375 |
| Market Cap | 260.033M |
| Beta | -0.33 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.90 |
| Earnings Date | Nov 6, 2017 - Nov 10, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.70 |
- GlobeNewswire•yesterday
Axovant to Present at Two Upcoming Investor Conferences
BASEL, Switzerland, Sept. 20, 2018-- Axovant Sciences today announced that Pavan Cheruvu, M.D., chief executive officer, will present a corporate overview at the Jefferies Gene Therapy Summit 2018 on September ...
- PR Newswire•4 days ago
Roivant Launches Respivant Sciences to Develop Innovative Therapeutics for Respiratory Diseases
BASEL, Switzerland and SAN DIEGO, Sept. 17, 2018 /PRNewswire/ -- Roivant Sciences today announced the launch of Respivant Sciences, a biopharmaceutical company focused on improving the lives of patients suffering from serious respiratory diseases. Respivant will be led by Chief Executive Officer Bill Gerhart, Executive Vice President for Clinical and Regulatory Ahmet Tutuncu, MD, PhD, and Executive Vice President for Development and Manufacturing Pravin Soni, PhD.
- Market Realist•7 days ago
What Spark Therapeutics’ Valuation Trend Indicates
Of the 22 analysts covering Spark Therapeutics in September, 11 of them have recommended a “buy” or higher, and nine have recommended a “hold.” Two analysts have given the stock a “sell” or lower rating. The mean rating for Spark stock is 2.41 with a target price of $69.67, implying an upside potential of 18% over its closing price of $59.04 on September 13. Its peers Esperion Therapeutics (ESPR), Intercept Pharmaceuticals (ICPT), and Axovant Sciences (AXON) have mean ratings of 2.27, 2.41, and 2.71, respectively, and target prices of $72.68, $123.07, and $4.70, respectively.
Market Realist•8 days agoInvestors Still Excited about Axovant
Axovant Sciences (AXON) is a clinical-stage biopharmaceutical company focused on acquiring, developing, and commercializing novel therapies in neurology and psychiatry. Its product candidates are targeted at neurological diseases, including Parkinson’s disease, oculopharyngeal muscular dystrophy, Lewy body dementia, and other indications. The former is a potential one-time treatment for Parkinson’s disease, and the latter is a potential one-time treatment for oculopharyngeal muscular dystrophy.
Market Realist•8 days agoAnalyzing Axovant Sciences’ Valuation Metrics
In September, there are seven analysts covering Axovant Sciences (AXON) stock. Two of them have given the stock a “buy” rating, and five have given it a “hold.” The mean rating for Axovant stock is 2.71 with a target price of $4.70, implying an upside potential of 129.3% over its trading price of $2.05 on September 11.
Market Realist•8 days agoAudentes Therapeutics’ Promising Product Pipeline
Gene therapy involves repairing or replacing disease-causing genes. Investor interest in gene therapy stocks has remained buoyant throughout 2018. According to Allied Market Research, the gene therapy market is expected to grow at a 33.3% CAGR (compound annual growth rate) to $4.4 billion by 2023.
Markit•20 days agoSee what the IHS Markit Score report has to say about Axovant Sciences Ltd.
Short interest is low for AXON with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
- GlobeNewswire•23 days ago
Axovant to Present at Upcoming Investor Conferences
BASEL, Switzerland, Aug. 29, 2018-- Axovant Sciences today announced that Pavan Cheruvu, M.D., chief executive officer, will participate in two upcoming investor conferences. Dr Cheruvu will present a ...
Markit•27 days agoSee what the IHS Markit Score report has to say about Axovant Sciences Ltd.
Short interest is low for AXON with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
- ACCESSWIRE•last month
Today's Research Reports on Stocks to Watch: Axovant Sciences and Gevo
NEW YORK, NY / ACCESSWIRE / August 22, 2018 / Gevo and Axovant Sciences had something in common on Tuesday. Axovant Sciences Ltd. was up 14.43% at the close on Tuesday on about 1.5 million shares traded.
Markit•last monthSee what the IHS Markit Score report has to say about Axovant Sciences Ltd.
Short interest is low for AXON with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
Market Realist•last monthPuma Biotechnology: Recent Developments and Recommendations
In June, the Committee for Medicinal Products for Human Use recommended a favorable opinion on the approval of Puma Biotechnology’s (PBYI) Nerlynx for its commercialization in the European Union for the prolonged adjuvant therapy of adults with early-stage HER2+ (hormone-receptor-positive) breast cancer whose prior adjuvant trastuzumab-based therapy is less than one year from completion.
- Associated Press•last month
Axovant: Fiscal 1Q Earnings Snapshot
On a per-share basis, the London-based company said it had a loss of 48 cents. In the final minutes of trading on Tuesday, the company's shares hit $2.08. A year ago, they were trading at $22.89. _____ ...
- GlobeNewswire•last month
Axovant Announces First Fiscal Quarter 2018 Financial Results and Corporate Update
Pipeline expanded with gene therapy technologies including AXO-Lenti-PD for treatment of Parkinson’ s Disease and AXO-AAV-OPMD for treatment of oculopharyngeal muscular dystrophy Ilise Lombardo, MD, promoted ...
Markit•2 months agoSee what the IHS Markit Score report has to say about Axovant Sciences Ltd.
Short interest is low for AXON with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
- Zacks•2 months ago
Options Traders Expect Huge Moves in Axovant Sciences (AXON) Stock
Investors in Axovant Sciences (AXON) need to pay close attention to the stock based on moves in the options market lately.
- Zacks•2 months ago
3 Gene Therapy Stocks Investors Can Bet on in Rest of 2018
Gene therapy continues to be in focus with the recent spate of deals and acquisitions. We highlight three stocks, which have promising candidates in their pipeline.
- Zacks•2 months ago
Biotech Stock Roundup: BIIB's Gain on Alzheimer's Data, Regulatory Updates & More
Biogen's results from a phase II study in the much-pursued Alzheimer's disease was all over the biotech sector last week.
- Zacks•2 months ago
Axovant, Benitec Gain on Licensing Deal for Gene Therapy
Axovant Sciences' (AXON) shares gain, following the news of a licensing deal for oculopharyngeal muscular dystrophy candidate with Benitec Biopharma.
Market Realist•2 months agoAxovant and Benitec Biopharma Up on Gene Therapy Development Deal
Axovant and Benitec Biopharma Rise on Gene Therapy Licensing DealAxovant and Benitec Biopharma enter into a licensing deal
- TheStreet.com•2 months ago
Axovant, Benetic Jump on Agreement to Develop Gene Therapy for MD
Shares of the biopharmaceutical company rose 5% in early morning trading Monday after it announced it had bought the rights to a new gene therapy treatment designed for a rare form of muscular dystrophy from Benitec Biopharma Ltd. Axovant rose 12 cents -- or 5% -- to $2.68 a share on news of the deal while Benitec skyrocketed $1.52 -- or 67.8% --$3.76. The two companies also entered into a research collaboration to develop five more treatments meant to target neurological disorders.
- GlobeNewswire•2 months ago
Axovant Announces Global Licensing Agreement for AXO-AAV-OPMD Program for Treatment of Oculopharyngeal Muscular Dystrophy and Broader Platform Collaboration with Benitec Biopharma
Axovant Sciences (AXON) today announced that it has licensed exclusive global rights to an investigational Silence-and-Replace gene therapy program from Benitec Biopharma for the treatment of oculopharyngeal muscular dystrophy (OPMD), and has also entered into a research collaboration for the development of five additional gene therapy products in neurological disorders. The Silence-and-Replace gene therapy technology is designed to deliver a combination of DNA-directed RNA interference (silence) along with a functional copy of the gene (replace) in a single vector construct.
- American City Business Journals•3 months ago
Biotech startup Roivant cuts staff, forms two new subsidiaries
Roivant Sciences, which raised $1.1 billion in equity last summer from the SoftBank Vision Fund and Founders Fund, has confirmed a round of layoffs. According to a prepared statement, the New York-based company said there has been a reduction in headcount of less than 10 percent of all employees. The announcement comes as the company also outlined that it has created two new business units — Roivant Pharma and Roivant Health.
- Motley Fool•3 months ago
Here's Why Axovant Sciences Fell as Much as 21.3% Today
The meteoric rise in recent weeks is proving unsustainable.
